Sanofi inks marketing pact with Emcure for cancer drugs

Tags: Companies
Drug firm Sanofi has entered into a marketing and distribution agreement with Emcure Pharmaceuticals for its oncology portfolio in India.

As per the agreement, Sanofi will continue to own its oncology range comprising four brands namely Taxotere, Jevtana, Fludara and Fasturtec, while Emcure will market and distribute these brands through its specialty unit, Sanofi India said in a filing to the BSE.

"Realising that managing the complexities of cancer necessitates the availability of a wide range of products and supporting therapies, we found that combining our efforts and product range with that of Emcure Oncology, makes immense sense for both companies," Sanofi Vice-President-South Asia and Sanofi India Managing Director Shailesh Ayyangar said.

Sanofi will continue to provide strong scientific and medical support to Emcure's already well-established and fast growing oncology business, he added.

Emcure Pharmaceuticals Managing Director Satish Mehta said: "We believe that the coming together of Sanofi's innovative oncology range with Emcure's oncology portfolio empowers us to provide an even wider array of value driven healthcare solutions."

Sanofi India Ltd shares were trading at Rs 2,886 a piece on the BSE in afternoon trade, up 0.27% from its previous close.

EDITORIAL OF THE DAY

  • The Muslim Personal Law Application Act needs an overhaul

    Triple talaq or khola as means to divorce or dissolve one’s marriage in the Muslim community is unacceptable, as the Allahabad High Court judgment s

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Sandeep Bamzai

<b>Disequilibrium:</b> THE GREAT GAMBLE

Finance it is said is merely a gun, politics is ...

Ananda Majumdar

<b>Ruminations:</b> BJP looks beyond muscular strategy

Gradually a new strategy for political management has been established ...

BK Chaturvedi

Committed, yet miles to go

Swachh Bharat is a mission to which everyone is committed. ...